Chapter 7

Shock, Resuscitation, and Vascular Access

Introduction
The goal of resuscitation is to maintain adequate perfusion. Resuscitation of the wounded combatant remains a formidable challenge on the battlefield. Routine initial resuscitation using 2 L of crystalloid through two large-bore IVs is not appropriate in all situations. In fact, blood transfusions may be part of the initial fluid resuscitation of casualties who bled or who were at high risk for ongoing bleeding. The vast majority of casualties do not need any IV fluid resuscitation prior to arrival at a forward medical treatment facility.

This chapter will briefly address shock (including recognition, classification, treatment, definition, and basic pathophysiology), review initial and sustained fluid resuscitation, summarize currently available fluids for resuscitation, and describe vascular access techniques.

Recognition and Classification of Shock
Shock is a clinical condition marked by inadequate organ perfusion and tissue oxygenation, manifested by poor skin turgor, pallor, cool extremities, capillary refill greater than 2 seconds, anxiety/confusion/obtundation, tachycardia, weak or thready pulse, and hypotension. Lab findings include base deficit >5 and lactic acidosis >2 mmol/L.

- Hypovolemic shock: Diminished volume resulting in poor perfusion as a result of hemorrhage, diarrhea, dehydration, and burns. This is the most common type of shock seen in combat casualties (Table 7-1).
Hypotension is a late finding in shock, occurring after 30%–40% blood volume loss. Earlier signs are tachycardia, decreased pulse pressure, and mental status changes. However, even these earlier signs may not be readily apparent in military casualties who generally have a greater propensity for physiological compensation secondary to physical conditioning.

<table>
<thead>
<tr>
<th>Size Designation: Blood Loss (cc):</th>
<th>Class I</th>
<th>Class II</th>
<th>Class III</th>
<th>Class IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood volume*</td>
<td>&lt;15%</td>
<td>15%–30%</td>
<td>30%–40%</td>
<td>&gt;40%</td>
</tr>
<tr>
<td>Pulse</td>
<td>&lt;100</td>
<td>&gt;100</td>
<td>&gt;120</td>
<td>&gt;140</td>
</tr>
<tr>
<td>BP</td>
<td>Normal</td>
<td>Normal</td>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td>Pulse pressure</td>
<td>Normal</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td>RR</td>
<td>14–20</td>
<td>20–30</td>
<td>30–40</td>
<td>&gt;35</td>
</tr>
<tr>
<td>UOP (cc/h)</td>
<td>&gt;30</td>
<td>20–30</td>
<td>5–15</td>
<td>Negligible</td>
</tr>
<tr>
<td>CNS</td>
<td>Normal</td>
<td>Anxious</td>
<td>Confused</td>
<td>Lethargic</td>
</tr>
</tbody>
</table>

BP: blood pressure; CNS: central nervous system; RR: respiratory rate; UOP: urine output.

*Blood volume is approximately 7% (eg, a 70-kg patient has a blood volume of 4,900 mL).

- **Cardiogenic shock:** Pump failure from intrinsic cardiac failure or obstructive cardiac dysfunction from a tension pneumothorax (unilateral absence breath sounds + distended neck veins) or cardiac tamponade (distended neck veins).
- **Distributive shock:** Poor perfusion due to loss of vascular tone.
  - **Neurogenic shock:** Bradycardia with hypotension, seen with spinal cord injury T6 and above due to loss of sympathetic tone and unopposed parasympathetic stimulation with resultant vasodilation.
  - **Septic shock:** Fever, hypotension, tachycardia, and warm extremities from massive vasodilation related to infection.
Treatment of Hypovolemic Shock—Control Bleeding!
The goal in the treatment of shock is to restore tissue perfusion and oxygen delivery (dependent on hemoglobin, cardiac output, and oxygenation).

- Secure the airway and administer oxygen for $\text{SaO}_2 < 92\%$.
- Diagnose and treat tension pneumothorax.
- Control obvious bleeding and assess for occult hemorrhage.
- Assess circulation and establish IV access.
  - Consider cardiac tamponade, even if there are no distended neck veins.
- Administer IV fluids.
  - Hemorrhagic shock: Resuscitate initially with any fluid available. But strong consideration must be given for early blood product transfusion, particularly in those casualties at risk for a massive transfusion (>10 units of PRBCs [packed red blood cells] in 24 hours).

  ◆ Physiological/laboratory predictors of massive transfusion include:
    ◇ Systolic blood pressure <110.
    ◇ Heart rate >105.
    ◇ Hematocrit <32%.
    ◇ pH < 7.25.
    ◇ 3 of 4 risk factors = 70% risk massive transfusion.
    ◇ 4 of 4 risk factors = 85% risk massive transfusion.

  ◆ Injury patterns associated for risk of massive transfusion include:
    ◇ Truncal/axillary/neck/groin bleeding not controlled by tourniquet or hemostatic dressings.
    ◇ Multiple amputations.
    ◇ Large soft-tissue injuries with uncontrolled bleeding.
    ◇ Large hemothorax.
    ◇ Large hemoperitoneum.

These patients should be immediately resuscitated with blood products (red blood cells:fresh frozen plasma:platelets) in a 1:1:1 ratio or consider fresh whole blood if full component therapy not available.
♦ See JTTS (Joint Theater Trauma System) Clinical Practice Guideline “Damage Control Resuscitation.”
♦ Types of IV fluids.
◊ Lactated Ringer’s (LR): 1,000 mL expands intravascular volume by only ~250 mL within 1 hour after infusion. Normal saline should be discouraged.
◊ Hextend (500 mL, Hetastarch 6% + a physiological balanced crystalloid carrier, including lactate buffer and glucose) expands intravascular volume by ~800 mL in 1 hour, is functionally equivalent to three bags of LR, and is sustained for at least 8 hours. May repeat once for a total of 1,000 mL.
◊ Hypertonic saline (HTS) 7.5% results in the same physiological response with one-eighth the volume of LR or saline. Two infusions of 250 cc can be used. Although this recommendation has been made by the Institute of Medicine (in Washington, DC) and two military consensus groups, HTS 7.5% is not commercially available. HTS 3% and HTS 5% can be used instead and are formulary stock items.

### Caveat-Hextend and HTS are effective primarily by shifting extracellular volume into intravascular space. They may be less effective if administrated in casualties with significant dehydration and require supplementation with judicious use of crystalloid.

◦ Isolated neurogenic shock.
  ♦ Intravascular resuscitation with crystalloid to maintain systolic mean arterial pressure >80 mm Hg or systolic blood pressure (SBP) >110.
  ◊ Recommend that crystalloid fluid resuscitation be used judiciously in this situation, since volume overload is associated with increased risk of pulmonary edema.
◦ Add a vasopressor after appropriate intravascular volume challenge (generally 2–3 L) to address the loss in vascular tone.
  ♦ Phenylephrine (50–300 µg/min).
  ♦ If bradycardic, consider dopamine (2–10 µg/kg/min).
Shock, Resuscitation, and Vascular Access

- Septic shock.
  - Initial resuscitation (first 12 hours).
    - Targets:
      - Mean arterial pressure ≥65 mm Hg or SBP ≥90.
      - Central venous pressure 8–12 mm Hg.
      - Urine output ≥0.5 mL/kg/h.
      - Central venous or mixed venous oxygen saturation ≥70%.
    - Begin intravenous antibiotics within the first hour of recognition of severe sepsis with broad-spectrum coverage.
    - Add a vasopressor after appropriate intravascular volume challenge usually until central venous pressure was 8–12 (generally up to 5 L crystalloid and/or colloid).
      - Norepinephrine initial dose 8–12 µg/min, then titrate to effect at 2–4 µg/min. (Sepsis [weight-based dosing] 0.01–3 µg/kg/min could be as much as 0.7–210 µg/min in 70-kg patient.)
      - Vasopressin 0.04 units/min (may titrate down for effect; do not titrate above maximum: 0.04 units/min).
    - Institute early acute lung injury/acute respiratory distress syndrome mechanical ventilation measures with low tidal volumes (5–7 cc/kg lean body mass) and end-inspiratory plateau pressures <30 cm H₂O.

- Subsequent therapy.
  - Overall fluid balance target after 12 hours of resuscitation is between 3–12 L. Greater than 12 L positive balance associated with increased mortality.
  - Consider blood transfusion if hemoglobin <7 to target hemoglobin of 7.0–9.0 g/dL.
  - Reassess antimicrobial regimen 48–72 hours after starting treatment with the objective of narrow-spectrum antibiotics.

- Based on response to fluids, casualties will fall into three groups: responders, transients, and nonresponders.
  - **Responders:** Casualties with a sustained response to fluids may have had significant blood loss, but have stopped bleeding. However, they may still require definitive surgery.
Transient and nonresponders are continuing to bleed. They need immediate surgical intervention.

- Start blood product transfusion as soon as possible, with a target goal ratio of 1:1:1 (PRBCs:fresh frozen plasma [FFP]:platelets).
- For nonresponders, fluids may be given to keep the casualty alive, but one should not attempt to restore pressure to normal. Consideration should be taken into account of the futility of the resuscitation, depending on the tactical scenario.
- Follow controlled resuscitation guidelines as presented in this chapter.

Exsanguinating hemorrhage is the cause of most preventable deaths during war. Combat casualties in shock should be assumed to have hemorrhagic shock until proven otherwise.

- Vasopressors have NO role in the initial treatment of hemorrhagic shock.
- Resuscitation fluid selection.
  - The ideal fluid for resuscitation is still debated, despite decades of research that began during World War I (Table 7-2).
  - Blood product transfusions should be considered early in the resuscitation, particularly in patients who have lost 30% or more of their blood volume. Blood products may also be necessary in patients who have not reached this threshold, but who have ongoing blood loss or who are at high risk of ongoing bleeding. Fresh whole blood therapy should be considered at levels of care where component blood product therapy (ie, PRBCs, FFP, platelets) is inadequate to meet the target goal ratio of 1:1:1.

Concept of Controlled Hypotensive Resuscitation / Permissive Hypotension

- Raising the blood pressure with fluid resuscitation may dislodge established clots leading to continued blood loss. Prior to establishing definitive hemorrhage control, use controlled resuscitation to achieve and maintain adequate perfusion as demonstrated by at least one of the following prioritized goals:
<table>
<thead>
<tr>
<th>Fluid/Initial Dose</th>
<th>Indication</th>
<th>Advantages</th>
<th>Cautions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Crystalloids</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saline</td>
<td>Hypovolemia, hemorrhage,</td>
<td>Easy to store, inexpensive, proven effectiveness, isotonic</td>
<td>Weight ratio—requires 3:1 for lost blood, dilution, edema, coagulopathy</td>
</tr>
<tr>
<td>Ringer’s lactate</td>
<td>shock, burns</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hypertonic saline</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3%-5%</td>
<td>Hemorrhagic shock: 4 cc/k</td>
<td>Lighter weight</td>
<td>&gt;500 cc—risk of hypernatremia, seizures</td>
</tr>
<tr>
<td>7.5%</td>
<td>or 250 cc bolus, may</td>
<td>Small volume = large effect</td>
<td>Do not use for dehydration from vomiting, diarrhea or sweating, or heat</td>
</tr>
<tr>
<td>HTS-colloid combinations*</td>
<td>repeat once</td>
<td>Increased cardiac contractility</td>
<td>injuries</td>
</tr>
<tr>
<td>HTS dextran*</td>
<td>Burns—only one dose</td>
<td>Longer duration of effect than plain HTS?</td>
<td>Do not repeat without addition of other fluids</td>
</tr>
<tr>
<td>HTS Hetastarch*</td>
<td>initially</td>
<td></td>
<td>Must replace depleted extravascular fluid</td>
</tr>
<tr>
<td><strong>Colloids</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Albumin</td>
<td>Hemorrhagic shock: (500-</td>
<td>Longer duration, 1:1 replacement for blood</td>
<td>Overuse may lead to “leak” into tissue</td>
</tr>
<tr>
<td>Artificial colloids</td>
<td>1,000 mL bolus)</td>
<td>Raises plasma oncotic pressure</td>
<td>Binds immunoglobulins and Ca^{2+}</td>
</tr>
<tr>
<td>Dextran</td>
<td>Burns, 3rd day</td>
<td>Recruits extravascular fluid</td>
<td>Must replace depleted extravascular fluid</td>
</tr>
<tr>
<td>6% Hetastarch (Hextend,</td>
<td>Hetastarch: coagulopathy,</td>
<td>Artificial colloids:</td>
<td></td>
</tr>
<tr>
<td>Hespan)</td>
<td>allergic reaction, osmotic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10% Pentastarch*</td>
<td>diuresis, interferes with</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gelatin-based colloids*</td>
<td>maximum dose: 20 mL/kg/d</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Oral rehydration fluids</strong></td>
<td>Dehydration-controlled</td>
<td>Fluids of opportunity</td>
<td></td>
</tr>
<tr>
<td>hemorrhage</td>
<td></td>
<td>Nonsterile ingredients: 4 tsp sugar, 1 tsp salt, 1 L water</td>
<td></td>
</tr>
<tr>
<td>Burns</td>
<td>Hemorrhage—type O</td>
<td>Carries oxygen</td>
<td></td>
</tr>
<tr>
<td>universal donor</td>
<td>universal donor</td>
<td>Autotransfusion</td>
<td></td>
</tr>
<tr>
<td>Blood</td>
<td>Hemorrhage</td>
<td>Walking blood bank</td>
<td></td>
</tr>
<tr>
<td>Artificial blood</td>
<td>Hemorrhage</td>
<td>Easy storage</td>
<td></td>
</tr>
<tr>
<td>Hemoglobin-based</td>
<td></td>
<td>No type and cross-matching</td>
<td></td>
</tr>
<tr>
<td>Fluorocarbon-based</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FDA: Food and Drug Administration; HTS: hypertonic saline. *Not FDA approved.

Regains consciousness (follows commands).
- Palpable radial pulse.
- SBP ~90 mm Hg.
- MAP (mean arterial pressure) ~60 mm Hg.

**Controlled resuscitation (permissive hypotension) is NOT a substitute for definitive surgical control. It is an attempt to keep a critically injured casualty alive until definitive treatment.**

- **Endpoints of resuscitation.**
  - Following definitive hemorrhage control, more traditional endpoints of resuscitation include:
    - Blood pressure: SBP >110–120 mm Hg, MAP >65–70 mm Hg.
    - Urine output: >0.5 mL/kg/h (approximately 30 mL/h).
    - Correction of acidosis by achieving base deficit <2 or serum lactate <2 mmol/L.
  - Hypothermia: It is important to maintain normal body temperature. Fluids, blood products, and casualty care areas must be warmed. Casualties frequently arrive to the facility hypothermic. Keep casualties covered when on litters, radiograph tables, and operating tables. External warmers should be used in all casualty care areas from initial emergency area through operating room and ICU. Hypothermia is much easier to prevent than it is to treat. See further discussion of hypothermia in Chapter 12, Damage Control Surgery. Also see JTTS Clinical Practice Guideline “Hypothermia Prevention.”

**Vascular Access**
- Vascular access is a critical early step in the management of trauma.
- Peripheral access should be attempted first; if unsuccessful, consider intraosseous (IO) device placement for initial resuscitation, followed by alternatives such as percutaneous central line (ie, subclavian, internal jugular, femoral veins) or “cutdowns” (saphenous vein either at the groin or ankle).
**Subclavian Vein Access or Internal Jugular Venipuncture**

- Place the casualty supine in the Trendelenburg position (15° head down).
- Prep and drape subclavian/jugular area. Sterile gloves must be worn. Use central line access kit.
  - Subclavian line.
    - With an index finger placed at the sternal notch, the thumb is placed at the junction of the medial and middle third of the clavicle.
    - 1% lidocaine is infiltrated into the skin, subcutaneous tissue, and periosteum of the clavicle.
    - Introduce a large caliber needle with an attached 5-mL syringe at the junction of the middle to lateral portion of the clavicle. Insert with the bevel of the needle up, directing the needle toward the contralateral clavicular head. Keep the needle horizontal to avoid a pneumothorax.
    - While aspirating, slowly advance the needle underneath the clavicle.
  - Jugular vein line.
    - Turn the casualty’s head 45° toward the contralateral side to expose the neck. Position must be altered to neutral position if concern for cervical spine injury.
    - Identify the apex of the anterior cervical triangle formed by the heads of the sternocleidomastoid muscle to locate the carotid artery.
    - Palpate the carotid artery and stay lateral with your venipuncture.
    - Introduce a large-bore needle on a 10-mL syringe at a 45° angle into the apex of the triangle, lateral to the carotid pulse.
    - Carotid puncture: Immediately withdraw the needle and place pressure on the site for a minimum of 5 minutes.
    - Advance the needle caudally, parallel to the sagittal plane and at a 30° posterior angle (eg, toward the ipsilateral nipple).
    - When free flow of venous blood appears, advance the needle an additional 4 mm (the length of the needle bevel), then remove the syringe and quickly cover the hub of the needle to prevent air embolism.
If air or arterial blood appears, stop immediately. Withdraw needle immediately and place pressure at the site for at least 5 minutes.

If no venous blood returns after advancing 5 cm, slowly withdraw the needle while aspirating. If this fails, redirect the needle.

- Subclavian vein or internal jugular vein catheter insertion.
  - Once the needle is in the vein, introduce the “J” wire through the needle (Seldinger technique). The wire should pass with minimal resistance. If the wire does not pass easily, withdraw the entire apparatus and reattempt line placement.
  - Remove the needle.
  - Enlarge the puncture site with a scalpel and dilator.
  - Pass the catheter over the wire while holding the wire in place to a depth of 18 cm on the left and 15 cm on the right for subclavian, and to a depth of 9 cm on the right and 12 cm on the left for jugular vein; then remove the wire.
  - Aspirate from all ports, flush all ports, suture in place, apply antibiotic ointment, dress area, secure tubing, and label date of insertion.
  - Chest radiograph to ensure line position and rule out pneumothorax.

Greater Saphenous Vein Cutdowns

- Contraindications.
  - Deep vein thrombosis or severe ipsilateral lower extremity trauma.
- Procedure.
  - Expose, prep, and drape ankle or femoral site.
  - For ankle, administer local anesthetic proximal to the medial malleolus.
  - Make a superficial transverse incision through the skin over the entire width of the flat tibial edge (~3 cm) in the area of the saphenous vein.
  - Using a curved hemostat, isolate the greater saphenous vein from the nerve and underlying bone.
o Using the open hemostat as a platform, cut a 1–2 mm venotomy in the anterior surface of the vein with a no. 11 blade (Fig. 7-1a).
o Place the intravenous tubing (previously beveled) or angiocatheter at least 4 cm into the vein (may require use of a vein introducer) (Fig. 7-1b).

Fig. 7-1. Saphenous vein cutdown.

o Secure the catheter with a proximal silk ligature and tie off the distal vein.
o Secure the catheter with a suture.
o Apply a clean dressing.
o The femoral procedure is essentially the same, with the site being a handbreadth below the inguinal ligament, medial to the midline of the thigh. After skin incision, the finger bluntly dissects through the fat to the fascia. Hook the finger and lift, and the vein comes up with it.

- Cutdown can also be performed on the common femoral veins, the jugular veins, and on veins of the forearm.

**Intraosseous Infusion**

- Contraindications.
  o Trauma or infection at insertion site.
Emergency War Surgery

- Excessive tissue or absence/inadequate anatomic landmarks.
- Recent IO device at the same site.
- Fracture of insertion bone.
- Recent sternotomy.

Devices/procedure.
- Procedure techniques vary based on model and can be either manual or power-driven.
  - Semiautomatic: Adult and pediatric Bone Injection Gun (B.I.G.)—spring-loaded, adult and pediatric EZ-IO—battery-powered drill.
  - Adult versus pediatric IO devices and needles are usually specified on the packaging labeling. Pediatric IO devices are only approved for the proximal and distal tibia.

Insertion location.
- Tibia: B.I.G., Cook, Sur-Fast, EZ-IO.
- Proximal humerus: EZ-IO.
- Sternum (manubrium): FAST1, sternal EZ-IO.

DO NOT USE HUMERAL OR TIBIAL IO DEVICES ON THE STERNUM.

- All IV fluids (except HTSs) and medications can be administrated via IO in similar rates to IV infusions.
- Confirm placement of IO by aspirating a small amount of blood and then flush with 10 mL of normal saline.

IO device placement is age and anatomically location-specific. Care must be taken to ensure IO device insertion is correlated to the packaging labeling instructions (eg, tibial IO cannot be used on the sternum because of the length of the needle).

- The IO device should be removed as soon as possible after other IV access is established, but definitely before 24 hours.

For Clinical Practice Guidelines, go to http://usaisr.amedd.army.mil/clinical_practice_guidelines.html